Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7613234 | 0.89 | CYP3A4 (0.54) | CYP3A4LMNAMTNR1AMTNR1BACHE | |
| SCHEMBL30631323 | 0.86 | PPARA (0.63) | CYP3A4LMNAMTNR1AMTNR1BPPARG | |
| SCHEMBL27865972 | 0.86 | PPARA (0.63) | CYP3A4LMNAMTNR1AMTNR1BPPARG | |
| SCHEMBL4268393 | 0.86 | CYP4F2 (0.56) | CYP3A4LMNAMTNR1AMTNR1BPPARG | |
| SCHEMBL30375077 | 0.85 | PPARA (0.62) | CYP3A4LMNAPPARGPPARA | |
| SCHEMBL1517301 | 0.85 | PPARA (0.66) | PPARGPPARAHDAC1HDAC6 | |
| SCHEMBL4279635 | 0.85 | CYP3A4 (0.50) | CYP3A4LMNAMTNR1AMTNR1BPPARG | |
| SCHEMBL7608883 | 0.85 | CYP4F2 (0.55) | CYP3A4LMNAMTNR1AMTNR1BPPARG | |
| SCHEMBL27853288 | 0.85 | PPARA (0.62) | CYP3A4LMNAPPARGPPARA | |
| SCHEMBL14445676 | 0.85 | PPARA (0.66) | PPARGPPARAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
| EP-1497261-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003091204-A1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | CYP3A4 543/4885LMNA 462/4885MTNR1A 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.